文献速递头颈部肿瘤放疗胸部肿瘤放疗

DNA-PK抑制剂Peposertib联合放疗伴或不伴顺铂治疗晚期头颈部肿瘤的1期研究

A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-09-24

这项1期试验评估了Peposertib联合姑息放疗(A组,胸部或头颈部肿瘤,n=34)或联合顺铂与根治性调强放疗(B组,头颈部鳞癌,n=11)的最大耐受剂量、2期推荐剂量(RP2D)、安全性和耐受性。A组最常见治疗中出现的不良事件为放射性皮肤损伤、乏力和恶心,RP2D为200 mg片剂每日一次联合放疗;B组50 mg被判定可耐受,但因该剂量暴露不足而终止入组,未正式确定RP2D。

要点

  • A组(n=34)RP2D为Peposertib片剂200 mg每日一次联合姑息放疗。
  • B组(n=11)50 mg联合顺铂与根治性放疗可耐受,但暴露不足终止入组,未正式确定RP2D。
  • A组常见不良事件为放射性皮肤损伤、乏力、恶心;B组为口腔黏膜炎、恶心、放射性皮肤损伤、味觉障碍。

核心结论

  • Peposertib联合姑息放疗在片剂每日一次200 mg联合每次放疗分次的剂量下耐受良好。
  • Peposertib联合放疗与顺铂时,可耐受剂量下暴露不足。

研究设计与样本

  • 1期试验(National Clinical Trial 02516813),Peposertib每日一次按递增剂量队列以片剂或胶囊给药。
  • A组为Peposertib联合姑息放疗治疗胸部或头颈部肿瘤患者(n=34)。
  • B组为Peposertib联合顺铂与根治性调强放疗治疗头颈部鳞状细胞癌患者(n=11)。

主要发现

  • A组(n=34)最常见的治疗中出现的不良事件为放射性皮肤损伤、乏力和恶心。
  • B组(n=11)最常见的治疗中出现的不良事件为口腔黏膜炎、恶心、放射性皮肤损伤和味觉障碍。
  • 基于剂量限制性毒性、耐受性和药代动力学数据,A组RP2D为Peposertib片剂200 mg每日一次联合放疗。
  • B组(n=11)中50 mg Peposertib联合根治性放疗与顺铂被判定可耐受,但因该剂量暴露不足而终止入组,RP2D未正式确定。

关键数值与推荐

  • A组RP2D:Peposertib片剂200 mg每日一次联合放疗。
  • B组:50 mg Peposertib联合根治性放疗与顺铂被判定可耐受,未正式确定RP2D。

局限性

  • B组因50 mg剂量下暴露不足而终止入组,RP2D未正式确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: DNA-dependent protein kinase (DNA-PK) plays a key role in the repair of DNA double strand breaks via nonhomologous end joining. Inhibition of DNA-PK can enhance the effect of DNA double strand break inducing anticancer therapies. Peposertib (formerly "M3814") is an orally administered, potent, and selective small molecule DNA-PK inhibitor that has demonstrated radiosensitizing and antitumor activity in xenograft models and was well-tolerated in monotherapy. This phase 1 trial (National Clinical Trial 02516813) investigated the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, and tolerability of peposertib in combination with palliative radiation therapy (RT) in patients with thoracic or head and neck tumors (arm A) and of peposertib in combination with cisplatin and curative-intent RT in patients with squamous cell carcinoma of the head and neck (arm B). METHODS AND MATERIALS: Patients received peposertib once daily in ascending dose cohorts as a tablet or capsule in combination with palliative RT (arm A) or in combination with intensity modulated curative-intent RT and cisplatin (arm B). RESULTS: The most frequently observed treatment-emergent adverse events were radiation skin injury, fatigue, and nausea in arm A (n = 34) and stomatitis, nausea, radiation skin injury, and dysgeusia in arm B (n = 11). Based on evaluations of dose-limiting toxicities, tolerability, and pharmacokinetic data, RP2D for arm A was declared as 200 mg peposertib tablet once daily in combination with RT. In arm B (n = 11), 50 mg peposertib was declared tolerable in combination with curative-intent RT and cisplatin. However, enrollment was discontinued because of insufficient exposure at that dose, and the RP2D was not formally declared. CONCLUSIONS: Peposertib in combination with palliative RT was well-tolerated up to doses of 200 mg once daily as tablet with each RT fraction. When combined with RT and cisplatin, a tolerable peposertib dose yielded insufficient exposure.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Samuels M, Falkenius J, Bar-Ad V, et al. A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors. Int J Radiat Oncol Biol Phys. 2023. PMID: 37751793. doi:10.1016/j.ijrobp.2023.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。